The pharmacotherapy for tic management in Tourette syndrome (TS) relies on neuroleptics, which have been associated with electrocardiographic abnormalities, including QTc interval prolongation. This study assessed the cardiovascular safety of the newer antipsychotic aripiprazole in comparison with the neuroleptic pimozide among young patients affected by TS. Fifty patients aged 6-18 years were assigned to either pimozide (n = 25; mean daily dose 4.4 mg/die) or aripiprazole (n = 25; 5.3 mg/die) treatment for up to 24 months. All patients underwent five serial cardiovascular assessments (baseline, 6, 12, 18 and 24 months). The group treated with pimozide showed significant changes in blood pressure (decreased), QT and QTc (both prolonged). The aripiprazole group showed changes from baseline to peak values in blood pressure (increased), whilst modifications in QT and QTc were not statistically significant. At equivalent doses, aripiprazole is characterised by a safer cardiovascular profile than pimozide, being associated with a lower frequency of QTc prolongation.

Gulisano, M., Calì, P., Cavanna, A., Eddy, C., Rickards, H., Rizzo, R. (2011). Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. NEUROLOGICAL SCIENCES, 32(6), 1213-1217 [10.1007/s10072-011-0678-1].

Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome

Cavanna A
;
2011

Abstract

The pharmacotherapy for tic management in Tourette syndrome (TS) relies on neuroleptics, which have been associated with electrocardiographic abnormalities, including QTc interval prolongation. This study assessed the cardiovascular safety of the newer antipsychotic aripiprazole in comparison with the neuroleptic pimozide among young patients affected by TS. Fifty patients aged 6-18 years were assigned to either pimozide (n = 25; mean daily dose 4.4 mg/die) or aripiprazole (n = 25; 5.3 mg/die) treatment for up to 24 months. All patients underwent five serial cardiovascular assessments (baseline, 6, 12, 18 and 24 months). The group treated with pimozide showed significant changes in blood pressure (decreased), QT and QTc (both prolonged). The aripiprazole group showed changes from baseline to peak values in blood pressure (increased), whilst modifications in QT and QTc were not statistically significant. At equivalent doses, aripiprazole is characterised by a safer cardiovascular profile than pimozide, being associated with a lower frequency of QTc prolongation.
Articolo in rivista - Articolo scientifico
Aripiprazole; Electrocardiogram; Pimozide; QTc interval; Tourette syndrome;
English
2011
32
6
1213
1217
reserved
Gulisano, M., Calì, P., Cavanna, A., Eddy, C., Rickards, H., Rizzo, R. (2011). Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. NEUROLOGICAL SCIENCES, 32(6), 1213-1217 [10.1007/s10072-011-0678-1].
File in questo prodotto:
File Dimensione Formato  
Gulisano-2011-Neurol Sci-VoR.pdf

Solo gestori archivio

Descrizione: Brief communication
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 162.33 kB
Formato Adobe PDF
162.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/413671
Citazioni
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 49
Social impact